To explore outcomes of stimulant treatment for ADHD in pediatric populations with particular attention to bipolar disorder (BPD).
Method:
We conducted a literature search of PubMed articles published prior to August 25, 2022 that focused on BPD, mania, and psychosis prior to, or as result of, stimulant treatment. We excluded studies: (1) unrelated to stimulants, (2) general stimulant research, (3) articles older than 40 years, (4) study protocols, or (5) case reports.
Results:
A total of 11 articles met all inclusion/exclusion criteria. Some reports found stimulant treatment safe and well-tolerated in children with comorbid BPD and ADHD. Others found evidence of treatment-emergent mania (TEM), discontinuation, and other adverse events with stimulant treatment.
Conclusion:
Poor outcomes associated with stimulant treatment in pediatric populations with BPD necessitate work to identify patients at risk of serious stimulant-related adverse events. Our results were limited by automated search filters and a pediatric, primarily male sample.
BaumerF. M.HoweM.GallelliK.SimeonovaD. I.HallmayerJ.ChangK. D. (2006). A pilot study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, risk factors, and the serotonin transporter gene. Biological Psychiatry, 60(9), 1005–1012. https://doi.org/10.1016/j.biopsych.2006.06.010
3.
Ben AmorL.SikiricaV.CloutierM.LachaineJ.GuerinA.CarterV.HodgkinsP.van StralenJ. (2014). Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec. The Journal of the Canadian Academy of Child and Adolescent Psychiatry, 23(3), 157–166.
4.
BhowmikD.AparasuR. R.RajanS. S.ShererJ. T.Ochoa-PerezM.ChenH. (2014). Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. Journal of Child and Adolescent Psychopharmacology, 24(10), 551–561. https://doi.org/10.1089/cap.2014.0028
5.
BiedermanJ.FaraoneS. V.PettyC.MartelonM.WoodworthK. Y.WozniakJ. (2013). Further evidence that pediatric-onset bipolar disorder comorbid with ADHD represents a distinct subtype: Results from a large controlled family study. Journal of Psychiatric Research, 47(1), 15–22. https://doi.org/10.1016/j.jpsychires.2012.08.002
6.
BiedermanJ.FaraoneS.WozniakJ.MickE.KwonA.AleardiM. (2004). Further evidence of unique developmental phenotypic correlates of pediatric bipolar disorder: Findings from a large sample of clinically referred preadolescent children assessed over the last 7 years. Journal of Affective Disorders, 82Suppl 1, S45–S58. https://doi.org/S0165-0327(04)00203-4[pii]10.1016/j.jad.2004.05.021
7.
BiedermanJ.MickE.SurmanC.DoyleR.HammernessP.HarpoldT.DunkelS.DoughertyM.AleardiM.SpencerT. (2006). A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 59(9), 829–835.
8.
BiedermanJ.SpencerT. J. (2008). Psychopharmacological interventions. Child and Adolescent Psychiatric Clinics of North America, 17(2), 439–458. https://doi.org/S1056-4993(07)00128-9[pii]10.1016/j.chc.2007.12.001
9.
BolandH.DiSalvoM.FriedR.WoodworthK. Y.WilensT.FaraoneS. V.BiedermanJ. (2020). A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of Psychiatric Research, 123, 21–30. https://doi.org/10.1016/j.jpsychires.2020.01.006
10.
BrikellI.WimberleyT.AlbiñanaC.PedersenE. M.VilhjálmssonB. J.AgerboE.DemontisD.BørglumA. D.SchorkA. J.LaBiancaS.WergeT.MorsO.HougaardD. M.ThaparA.MortensenP. B.DalsgaardS. (2021). Genetic, clinical, and sociodemographic factors associated with stimulant treatment outcomes in ADHD. The American Journal of Psychiatry, 178(9), 854–864. https://doi.org/10.1176/appi.ajp.2020.20121686
11.
ChakrabortyK.GroverS. (2011). Methylphenidate-induced mania-like symptoms. Indian Journal of Pharmacology, 43(1), 80–81. https://doi.org/10.4103/0253-7613.75678
12.
CorrP. J.KumariV. (2000). Individual differences in mood reactions to d-amphetamine: A test of three personality factors. Journal of Psychopharmacology, 14(4), 371–377. https://doi.org/10.1177/026988110001400406
13.
DelBelloM. P.SoutulloC. A.HendricksW.NiemeierR. T.McElroyS. L.StrakowskiS. M. (2001). Prior stimulant treatment in adolescents with bipolar disorder: Association with age at onset. Bipolar Disorder, 3(2), 53–57. https://doi.org/10.1034/j.1399-5618.2001.030201.x
14.
DemontisD.WaltersG. B.AthanasiadisG.WaltersR.TherrienK.NielsenT. T.FarajzadehL.VoloudakisG.BendlJ.ZengB.ZhangW.GroveJ.AlsT. D.DuanJ.SatterstromF. K.Bybjerg-GrauholmJ.Bækved-HansenM.GudmundssonO. O.MagnussonS. H.. . . BørglumA. D. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat Genet, 55(2), 198–208. https://doi.org/10.1038/s41588-022-01285-8
15.
DilerR. S.DavissW. B.LopezA.AxelsonD.IyengarS.BirmaherB. (2007). Differentiating major depressive disorder in youths with attention deficit hyperactivity disorder. Journal of Affective Disorders, 102(1–3), 125–130. https://doi.org/10.1016/j.jad.2007.01.002
16.
FaeddaG. L.BaldessariniR. J.GlovinskyI. P.AustinN. B. (2004). Treatment-emergent mania in pediatric bipolar disorder: A retrospective case review. Journal of Affective Disorders, 82(1), 149–158. https://doi.org/10.1016/j.jad.2003.12.011
17.
FaraoneS. V.BiedermanJ.MenninD.WozniakJ.SpencerT. (1997). Attention-deficit hyperactivity disorder with bipolar disorder: A familial subtype?Journal of the American Academy of Child and Adolescent Psychiatry, 36(10), 1378–1387; discussion 1387–1390.
18.
FaraoneS. V.BiedermanJ.SpencerT. J.AleardiM. (2006). Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine, 8(4), 4. https://www.ncbi.nlm.nih.gov/pubmed/17415287
19.
FaraoneS. V.BiedermanJ.WozniakJ. (2012). Examining the comorbidity between attention deficit hyperactivity disorder and bipolar I disorder: A meta-analysis of family genetic studies. The American Journal of Psychiatry, 169(12), 1256–1266. https://doi.org/1461101[pii]10.1176/appi.ajp.2012.12010087
20.
FindlingR. L.ShortE. J.McNamaraN. K.DemeterC. A.StansbreyR. J.GraciousB. L.WHipkeyR.ManosM. J.CalabreseJ. R. (2007). Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(11), 1445–1453.
21.
FredriksenM.HalmøyA.FaraoneS. V.HaavikJ. (2013). Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. European Neuropsychopharmacology, 23(6), 508–527. https://doi.org/10.1016/j.euroneuro.2012.07.016
22.
FroehlichT. E.BrinkmanW. B.PeughJ. L.PiedraA. N.VitucciD. J.EpsteinJ. N. (2020). Pre-existing comorbid emotional symptoms moderate short-term methylphenidate adverse effects in a randomized trial of children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 30(3), 137–147. https://doi.org/10.1089/cap.2019.0125
23.
GajriaK.LuM.SikiricaV.GrevenP.ZhongY.QinP.XieJ. (2014). Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatric Disease and Treatment, 10, 1543–1569. https://doi.org/10.2147/NDT.S65721ndt-10-1543[pii]
24.
GalanterC. A.CarlsonG. A.JensenP. S.GreenhillL. L.DaviesM.LiW.ChuangS. Z.ElliottG. R.ArnoldL. E.MarchJ. S.HechtmanL.PelhamW. E.SwansonJ. M. (2003). Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology, 13(2), 123–136.
25.
GreenhillL. L.FindlingR. L.SwansonJ. M. (2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 109(3), E39.
26.
HaddawayN. R.PageM. J.PritchardC. C.McGuinnessL. A. (2022). PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews, 18(2), e1230. https://doi.org/https://doi.org/10.1002/cl2.1230
27.
HamidovicA.ChildsE.ConradM.KingA.de WitH. (2010). Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. Drug and Alcohol Dependence, 109(1–3), 175–180. https://doi.org/10.1016/j.drugalcdep.2009.12.029
28.
HenningA.KurtomM.EspiridionE. D. (2019). A case study of acute stimulant-induced psychosis. Cureus, 11(2), e4126. https://doi.org/10.7759/cureus.4126
29.
KimM. L.DalviN.ValerioD. D.StricklerG. K.YoungL. D. (2023). Prescribed stimulant medications: Trends in the last decade, pre and post COVID-19 response. Exploratory Research in Clinical and Social Pharmacy, 11, 100314. https://doi.org/https://doi.org/10.1016/j.rcsop.2023.100314
30.
Koehler-TroyC.StroberM.MalenbaumR. (1986). Methylphenidate-induced mania in a prepubertal child. The Journal of Clinical Psychiatry, 47(11), 566–567.
MadjarN.ShlosbergD.Leventer-RobertsM.AkrivA.GhilaiA.HoshenM.KrivoyA.ZalsmanG.ShovalG. (2019). Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence. European Child & Adolescent Psychiatry, 28(10), 1365–1373. https://doi.org/10.1007/s00787-019-01301-z
33.
MoranL. V.OngurD.HsuJ.CastroV. M.PerlisR. H.SchneeweissS. (2019). Psychosis with methylphenidate or amphetamine in patients with ADHD. The New England Journal of Medicine, 380(12), 1128–1138. https://doi.org/10.1056/NEJMoa1813751
34.
MosholderA. D.GelperinK.HammadT. A.PhelanK.Johann-LiangR. (2009). Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics, 123(2), 611–616. https://doi.org/10.1542/peds.2008-0185
PostR. M.LeverichG. S.KupkaR. W.KeckP. E.Jr.McElroyS. L.AltshulerL. L.FryeM. A.LuckenbaughD. A.RoweM.GrunzeH.SuppesT.NolenW. A. (2010). Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. The Journal of Clinical Psychiatry, 71(7), 864–872. https://doi.org/10.4088/JCP.08m04994yel
38.
RieraM.CastellsX.TobiasA.CunillR.BlancoL.CapellàD. (2017). Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: Meta-analysis of 63 studies enrolling 11,788 patients. Psychopharmacology, 234(17), 2657–2671. https://doi.org/10.1007/s00213-017-4662-1
39.
Roborel de ClimensA.PainE.BossA.ShaunikA. (2020). Understanding reasons for treatment discontinuation, attitudes and education needs among people who discontinue type 2 diabetes treatment: Results from an online patient survey in the USA and UK. Diabetes Therapy, 11(8), 1873–1881. https://doi.org/10.1007/s13300-020-00843-9
40.
RossR. G. (2006). Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. The American Journal of Psychiatry, 163(7), 1149–1152. https://doi.org/10.1176/ajp.2006.163.7.1149
41.
SoutulloC. A.DelBelloM. P.OchsnerJ. E.McElroyS. L.TaylorS. A.StrakowskiS. M.KeckP. E. (2002). Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. Journal of Affective Disorders, 70(3), 323–327. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=12128245
van HulzenK. J.ScholzC. J.FrankeB.RipkeS.KleinM.McQuillinA.Sonuga-BarkeE. J.GroupP. A. W.KelsoeJ. R.LandenM.AndreassenO. A.GroupP. G. C. B. D. W.LeschK. P.WeberH.FaraoneS. V.Arias-VasquezA.ReifA. (2016). Genetic overlap between attention-deficit/hyperactivity disorder and bipolar disorder: Evidence from genome-wide association study meta-analysis. Biological Psychiatry, 82, 634–641. https://doi.org/10.1016/j.biopsych.2016.08.040
44.
ViktorinA.RydénE.ThaseM. E.ChangZ.LundholmC.D’OnofrioB. M.AlmqvistC.MagnussonP. K.LichtensteinP.LarssonH.LandénM. (2017). The risk of treatment-emergent mania with methylphenidate in bipolar disorder. The American Journal of Psychiatry, 174(4), 341–348. https://doi.org/10.1176/appi.ajp.2016.16040467
45.
WigalT.GreenhillL.ChuangS.McGoughJ.VitielloB.SkrobalaA.SwansonJ.WigalS.AbikoffH.KollinsS.McCrackenJ.RiddleM.PosnerK.GhumanJ.DaviesM.ThorpB.StehliA. (2006). Safety and tolerability of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1294–1303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17028508
46.
WilensT.BiedermanJ.BrownS.TanguayS.MonuteauxM.BlakeC.SpencerT. (2002). Psychiatric comorbidity and functioning in clinically referred preschoolers and school aged youth with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 41(3), 262–268.
47.
WozniakJ.BiedermanJ.KielyK.AblonS.FaraoneS.MundyE.MenninD. (1995). Mania-like symptoms suggestive of childhood onset bipolar disorder in clinically referred children. Journal of the American Academy of Child and Adolescent Psychiatry, 34(7), 867–876. https://doi.org/S0890-8567(09)63597-8[pii]10.1097/00004583-199507000-00010
48.
ZeniC. P.TramontinaS.KetzerC. R.PheulaG. F.RohdeL. A. (2009). Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: A randomized crossover trial [Randomized controlled trial research support, non-u.S. Gov’t]. Journal of Child and Adolescent Psychopharmacology, 19(5), 553–561. https://doi.org/10.1089/cap.2009.0037
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
